# Research Alliance Corp III (RACC) — merger/spac_merger [pending]
Source: SEC API (secapi.ai) · situation sit_4abf10349ff663d148dd · retrieved 2026-08-11T15:52:21.053Z

## Overview
Oak Hill Bio develops rugonersen, an investigational antisense oligonucleotide therapy for Angelman syndrome, a rare genetic neurodevelopmental disorder affecting approximately 1 in 15,000 births; the company licensed the asset from Roche in 2025.

Oak Hill Bio (OHB Pediatrics Ltd), a rare disease biotech developing rugonersen for Angelman syndrome, announced a merger with Research Alliance Corporation III (RACC), a RA Capital-sponsored blank-check company. The combined entity will raise $175 million in total funding: $75 million from RACC's trust account and $100 million in committed private financing from RA Capital and other investors. Oak Hill will use the proceeds alongside its recent $32.5 million Series A financing to advance rugonersen through its Phase 3 BEACON trial, with data expected by the first quarter of 2029. The merger is expected to close by the end of 2026, and the combined company will trade on Nasdaq under the ticker symbol OAKH.

## Terms
- Counterparty: Research Alliance Corporation III · Deal value: $175.0M · Consideration: cash

## Key dates
- Announced 2026-07-28 · Expected close 2026-12-31

## Timeline
- 2026-07-28 · 425 (0001193125-26-318558): 425 - Research Alliance Corp III — *OHB Pediatrics Ltd. is a company incorporated under the laws of England and Wales engaged in pediatric pharmaceutical development and commercialization.* Research Alliance Corporation III (RACC), a Cayman Islands exempted company, entered into a Business Combination Agreement dated July 26, 2026, with OHB Pediatrics Ltd., an England and Wales company, and OHB's shareholders. The proposed merger will be submitted to RACC shareholders for approval. RACC intends to file a registration statement on Form S-4 with the SEC, which will include a proxy statement/prospectus for shareholders to vote on the transaction. The definitive proxy statement and related documents will be mailed to RACC shareholders after the registration statement is declared effective.
  https://www.sec.gov/Archives/edgar/data/2118032/0001193125-26-318558.txt
- 2026-08-05 · 425 (0001193125-26-335338): 425 - Research Alliance Corp III — *Oak Hill Bio develops rugonersen, an investigational antisense oligonucleotide therapy for Angelman syndrome, a rare genetic neurodevelopmental disorder affecting approximately 1 in 15,000 births; the company licensed the asset from Roche in 2025.* Oak Hill Bio (OHB Pediatrics Ltd), a rare disease biotech developing rugonersen for Angelman syndrome, announced a merger with Research Alliance Corporation III (RACC), a RA Capital-sponsored blank-check company. The combined entity will raise $175 million in total funding: $75 million from RACC's trust account and $100 million in committed private financing from RA Capital and other investors. Oak Hill will use the proceeds alongside its recent $32.5 million Series A financing to advance rugonersen through its Phase 3 BEACON trial, with data expected by the first quarter of 2029. The merger is expected to close by the end of 2026, and the combined company will trade on Nasdaq under the ticker symbol OAKH.
  https://www.sec.gov/Archives/edgar/data/2118032/0001193125-26-335338.txt

## Citations
- 0001193125-26-318558 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526318558
- 0001193125-26-335338 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526335338